PALO ALTO, Calif., May 8 /PRNewswire/ -- Anacor Pharmaceuticals
announced today that it will present six posters on topical
anti-inflammatory candidates, AN2728 and AN2898, at the upcoming
International Investigative Dermatology 2008 Conference, taking place May
14-17, 2008 in Kyoto, Japan. The IID Conference is the Fifth Joint Meeting
of the European Society for Dermatological Research (ESDR), the Japanese
Society for Investigative Dermatology (JSID) and the Society for
Investigative Dermatology (SID).
Poster Session 1: Friday May 16, 5:30-7 p.m.
Poster title (#89): In vitro activity and mechanism of action of AN2728,
a novel oxaborole in development for treatment of psoriasis
Poster title (#367): AN2728, a novel oxaborole in development for
treatment of psoriasis, demonstrates significant activity in a micro
Poster Session 2: Saturday May 17, 1:15-2:45 p.m.
Poster title (#84): Preclinical toxicology of AN2728, a novel oxaborole
in development for the topical treatment of psoriasis
Poster title (#86): AN2898, a novel oxaborale compound with
anti-inflammatory activity: mechanism of action and in vitro cytokine
Poster title (#88): Structure-activity studies of AN2728 and AN2898,
novel oxaborole compounds with anti-inflammatory activities
Poster title (#90): AN2898, a novel oxaborale compound with
anti-inflammatory activity: results of in vivo efficacy and preclinical
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule
therapeutics derived from its boron chemistry platform. Anacor has focused
initially on developing topical applications of its compounds to treat
fungal, bacterial and inflammatory diseases. Anacor's most advanced product
candidate is AN2690, a novel topical antifungal in development for th
|SOURCE Anacor Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved